share_log

石藥集團：石藥創新製藥股份有限公司截至2024年9月30日止9個月之未經審計財務資料

CSPC PHARMA: UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024

HKEX ·  Oct 23 18:14

Summary by Futu AI

石藥集團旗下附屬公司石藥創新製藥股份有限公司（簡稱「石藥創新」，股票代碼：300765）於2024年10月23日發佈了截至2024年9月30日止9個月的未經審計第三季度報告。該報告顯示，石藥創新在報告期內的營業收入較上年同期下降了14.48%，而歸屬於上市公司股東的淨利潤更是大幅下滑了98.03%。此外，基本每股收益和稀釋每股收益均下降了超過97%。石藥創新的財務狀況顯示，其貨幣資金、應收款項融資、以及應付帳款等項目均出現了顯著變動，其中貨幣資金減少了65.69%，主要原因是公司購買大額定期存單、進行股份回購、現金分紅以及支付研發款項等。石藥集團強調，該財務報告僅反映石藥創新的財務狀況，並非石藥集團整體的財務資料，提醒投資者在買賣本公司證券時應審慎行事。
石藥集團旗下附屬公司石藥創新製藥股份有限公司（簡稱「石藥創新」，股票代碼：300765）於2024年10月23日發佈了截至2024年9月30日止9個月的未經審計第三季度報告。該報告顯示，石藥創新在報告期內的營業收入較上年同期下降了14.48%，而歸屬於上市公司股東的淨利潤更是大幅下滑了98.03%。此外，基本每股收益和稀釋每股收益均下降了超過97%。石藥創新的財務狀況顯示，其貨幣資金、應收款項融資、以及應付帳款等項目均出現了顯著變動，其中貨幣資金減少了65.69%，主要原因是公司購買大額定期存單、進行股份回購、現金分紅以及支付研發款項等。石藥集團強調，該財務報告僅反映石藥創新的財務狀況，並非石藥集團整體的財務資料，提醒投資者在買賣本公司證券時應審慎行事。
CSPC Pharma subsidiary CSPC Innovation Pharmaceutical Co., Ltd. (referred to as 'CSPC Innovation', stock code: 300765) released the unaudited third-quarter report for the nine months ended September 30, 2024 on October 23, 2024. The report shows that CSPC Innovation's revenue for the reporting period decreased by 14.48% compared to the same period last year, and the net profit attributable to shareholders of the listed company plummeted by 98.03%. In addition, both the basic EPS and diluted EPS dropped by over 97%. The financial situation of CSPC Innovation indicates significant changes in items such as monetary funds, accounts receivable financing, and accounts payable, with a 65.69% decrease in monetary funds. The main reasons include the company's large purchases of time deposits, share repurchases, cash dividends, and R&D payments. CSPC Pharma emphasizes that this financial report only reflects the financial condition of CSPC Innovation, not the overall financial data of CSPC Pharma, and reminds investors to act cautiously when trading the company's securities.
CSPC Pharma subsidiary CSPC Innovation Pharmaceutical Co., Ltd. (referred to as 'CSPC Innovation', stock code: 300765) released the unaudited third-quarter report for the nine months ended September 30, 2024 on October 23, 2024. The report shows that CSPC Innovation's revenue for the reporting period decreased by 14.48% compared to the same period last year, and the net profit attributable to shareholders of the listed company plummeted by 98.03%. In addition, both the basic EPS and diluted EPS dropped by over 97%. The financial situation of CSPC Innovation indicates significant changes in items such as monetary funds, accounts receivable financing, and accounts payable, with a 65.69% decrease in monetary funds. The main reasons include the company's large purchases of time deposits, share repurchases, cash dividends, and R&D payments. CSPC Pharma emphasizes that this financial report only reflects the financial condition of CSPC Innovation, not the overall financial data of CSPC Pharma, and reminds investors to act cautiously when trading the company's securities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated